Tags

Type your tag names separated by a space and hit enter

Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity.
CNS Drugs. 2014 May; 28(5):389-99.CD

Abstract

Calcitonin gene-related peptide (CGRP) is a well-studied neuropeptide of relevance for migraine pathophysiology. Jugular levels of CGRP are increased during migraine attacks, and intravenous CGRP administration induces migraine-like headache in most individuals with migraine. Several CGRP receptor antagonists (CGRP-RAs) were shown to be effective for the acute treatment of migraine, validating the target for the treatment of migraine. However, for a number of reasons, including issues of liver toxicity with chronic use, the development of CGRP-RAs has yet to produce a viable clinical therapeutic. Development of monoclonal antibodies (mAbs) targeting the CGRP pathway is an alternative approach that should avoid many of the issues seen with CGRP-RAs. The exquisite target specificity, prolonged half-lives, and reduced potential for hepatotoxicity and drug-drug interactions make mAbs suitable for the preventive treatment of migraine headaches. This manuscript provides an overview of the role of CGRP in the pathophysiology of migraine, followed by a review of the clinical development of CGRP-RAs. Some basic concepts on antibodies are then discussed along with the publicly disclosed information on the development of mAbs targeting the CGRP pathway.

Authors+Show Affiliations

Labrys Biologics Inc, 1810 Gateway Drive, Suite 230, San Mateo, CA, USA, mbigal@labrysbiologics.com.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

24638916

Citation

Bigal, Marcelo E., and Sarah Walter. "Monoclonal Antibodies for Migraine: Preventing Calcitonin Gene-related Peptide Activity." CNS Drugs, vol. 28, no. 5, 2014, pp. 389-99.
Bigal ME, Walter S. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. CNS Drugs. 2014;28(5):389-99.
Bigal, M. E., & Walter, S. (2014). Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. CNS Drugs, 28(5), 389-99. https://doi.org/10.1007/s40263-014-0156-4
Bigal ME, Walter S. Monoclonal Antibodies for Migraine: Preventing Calcitonin Gene-related Peptide Activity. CNS Drugs. 2014;28(5):389-99. PubMed PMID: 24638916.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. AU - Bigal,Marcelo E, AU - Walter,Sarah, PY - 2014/3/19/entrez PY - 2014/3/19/pubmed PY - 2015/1/15/medline SP - 389 EP - 99 JF - CNS drugs JO - CNS Drugs VL - 28 IS - 5 N2 - Calcitonin gene-related peptide (CGRP) is a well-studied neuropeptide of relevance for migraine pathophysiology. Jugular levels of CGRP are increased during migraine attacks, and intravenous CGRP administration induces migraine-like headache in most individuals with migraine. Several CGRP receptor antagonists (CGRP-RAs) were shown to be effective for the acute treatment of migraine, validating the target for the treatment of migraine. However, for a number of reasons, including issues of liver toxicity with chronic use, the development of CGRP-RAs has yet to produce a viable clinical therapeutic. Development of monoclonal antibodies (mAbs) targeting the CGRP pathway is an alternative approach that should avoid many of the issues seen with CGRP-RAs. The exquisite target specificity, prolonged half-lives, and reduced potential for hepatotoxicity and drug-drug interactions make mAbs suitable for the preventive treatment of migraine headaches. This manuscript provides an overview of the role of CGRP in the pathophysiology of migraine, followed by a review of the clinical development of CGRP-RAs. Some basic concepts on antibodies are then discussed along with the publicly disclosed information on the development of mAbs targeting the CGRP pathway. SN - 1179-1934 UR - https://www.unboundmedicine.com/medline/citation/24638916/Monoclonal_antibodies_for_migraine:_preventing_calcitonin_gene_related_peptide_activity_ L2 - https://dx.doi.org/10.1007/s40263-014-0156-4 DB - PRIME DP - Unbound Medicine ER -